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Background: This multi-centre, prospective, randomized, double-blind, placebo-controlled study was designed to
test the hypotheses that parecoxib improves patients’ postoperative analgesia without increasing surgical blood loss
following radical open prostatectomy.
Methods: 105 patients (64 ± 7 years old) were randomized to receive either parecoxib or placebo with concurrent
morphine patient controlled analgesia. Cumulative opioid consumption (primary objective) and the overall benefit
of analgesia score (OBAS), the modified brief pain inventory short form (m-BPI-sf), the opioid-related symptom
distress scale (OR-SDS), and perioperative blood loss (secondary objectives) were assessed.
Results: In each group 48 patients received the study medication for 48 hours postoperatively. Parecoxib significantly
reduced cumulative opioid consumption by 24% (43 ± 24.1 mg versus 57 ± 28 mg, mean ± SD, p=0.02), translating
into improved benefit of analgesia (OBAS: 2(0/4) versus 3(1/5.25), p=0.01), pain severity (m-BPI-sf: 1(1/2) versus 2(2/3),
p < 0.01) and pain interference (m-BPI-sf: 1(0/1) versus 1(1/3), p=0.001), as well as reduced opioid-related side effects
(OR-SDS score: 0.3(0.075/0.51) versus 0.4(0.2/0.83), p=0.03). Blood loss was significantly higher at 24 hours following
surgery in the parecoxib group (4.3 g⋅dL−1 (3.6/4.9) versus (3.2 g⋅dL−1 (2.4/4.95), p=0.02).
Conclusions: Following major abdominal surgery, parecoxib significantly improves patients’ perceived analgesia.
Parecoxib may however increase perioperative blood loss. Further trials are needed to evaluate the effects of selective
cyclooxygenase-2 inhibitors on blood loss.
Trial registration: ClinicalTrials.gov Identifier: NCT00346268
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Ineffective postoperative pain control still remains an
unsolved problem [1], resulting in prolonged hospital
stay and increased hospital costs [2]. Individualized, pro-
cedure specific postoperative analgesia has been advo-
cated in order to solve this issue [3]. However, despite
the growing evidence that there are procedure specific
differences in postoperative pain, guidelines are general-
ized for most surgical procedures [3] and opioids are be-
ing used as the mainstay of analgesia [4]. However, their
use is associated with well known side effects, which* Correspondence: Daniel.Dirkmann@uk-essen.de
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unless otherwise stated.may affect patient satisfaction, length of hospital stay,
and increase cost of care [5,6]. Non-steroidal anti-
inflammatory drugs (NSAIDs), decrease perioperative
opioid consumption and opioid-related side effects [7].
However, their use is associated with adverse events
such as surgical bleeding and ulcer formation [7]. Select-
ive cyclooxygenase-2 (COX-2) inhibitors have been pro-
posed to be a safe alternative for several years. Parecoxib
(a prodrug of valdecoxib) is a parenterally selective
cyclooxygenase-2 (COX-2) inhibitor that reduces post-
operative opioid consumption, following thyroid surgery
[8], hernia repair [9], gynecological laparotomy [10],
total hip [11] and knee arthroplasty [12], as well as spine
surgery [13]. However, the use of parecoxib in cardiac
surgery has been associated with an increased incidenceral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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thermore, long-term use of two other COX-2 inhibitors
(namely celecoxib and rofecoxib) has been associated with
an increased cardiovascular risk in large trials that sought
to assess the preventive effects of these drugs on colorec-
tal adenoma development [16,17]. In addition, there are
data suggesting that COX-2 inhibitors may increase peri-
operative blood loss in non cardiac surgery [11].
The discovery of fraud in the publications by Reuben
et al. and the subsequent retraction of 21 peer-reviewed
articles on perioperative analgesia, raised additional se-
vere concerns about what is still known about risks and
benefits of COX-2 inhibitor treatment [18] and the val-
idity of review articles including such fraudulent data
has been questioned [19]. Accordingly, it seems import-
ant to gather additional perioperative data to better de-
fine the risk-benefit ratio of COX-2 inhibitor treatment
in a procedure-specific fashion.
This multi-centre, prospective, randomized, double-
blind, placebo-controlled study was designed to test the
hypotheses that parecoxib improves patients’ postopera-
tive analgesia without increasing surgical blood loss fol-
lowing radical open prostatectomy. The reduction of
morphine consumption during the first 48 postoperative
hours was defined as the primary objective. Patients’ bene-
fit of analgesia, reduced pain severity and pain interfer-
ence, as well as reduced opioid related side effects, as
assessed by respective validated scores, were chosen as
secondary objecitves. Furthermore, the effects of pare-
coxib on blood loss, as measured by the peri-and postop-
erative decrease in the serum hemoglobin concentration
were defined as a secondary objective, given the conflict-
ing evidence in the literature on this side-effect of COX-2
inhibitors.Methods
This investigator initiated, multi-centric, prospective,
double-blind, placebo-controlled study was conducted in
compliance with the ‘Declaration of Helsinki’ and accord-
ing to ‘Good Clinical Practice’ guidelines, at three German
hospitals. Patients were recruited between December 2006
and September 2010, when the study was prematurely ter-
minated due to slow recruitment as a result of increasing
use of robot assisted surgery at all investigational centers.
The study was funded by Pfizer, Germany. Pfizer was
involved in the generation of the study design. How-
ever, Pfizer did not influence the interpretation and the
discussion of results. The study was registered at www.
clinicaltrials.gov (Identifier: NCT00346268). The study
was reviewed and approved by the ethics committee of
the University Duisburg-Essen (Ethik-Komission der
Universität Duisburg Essen, Robert-Koch-Straße 9–11,
45147 Essen, Germany, protocol number: A3481066,date of approval 25.09.2006). All patients gave written
informed consent.
Inclusion and exclusion criteria
We included patients scheduled for elective radical open
prostatectomy with an American Society of Anesthesiol-
ogists (ASA) physical status of I or II, who did not have
a high risk of developing an acute coronary event within
the next 10 years, according to the Prospective Cardio-
vascular Münster Heart Study (PROCAM) [20].
To help improve the validity of our results whilst
maximizing patient safety, patients with congestive heart
failure or established ischemic heart disease, peripheral
and/or cerebrovascular arterial disease, or those with a
history of coronary artery bypass graft (CABG) proced-
ure were excluded. Additional exclusion criteria were a his-
tory of asthma or bronchospasm that required treatment
with oral glucocorticoids, inflammatory bowel disease,
chronic or acute renal or hepatic disease, coagulopathy,
and adverse events after previously taking acetylsalicylic
acid NSAIDs. We did not include patients with active or
suspected gastrointestinal ulceration or bleeding, or a his-
tory of alcohol, analgesic, or narcotic abuse. Furthermore,
individuals with known laboratory abnormality of aspartate
aminotransferase (AST) or serum glutamic oxaloacetic
transaminase [SGOT]) or alanine aminotransferase (ALT)
or serum glutamic pyruvic transaminase [SGPT]) greater
than 1.5 times the upper limit normal, or creatinine greater
than 1.5 times the upper limit of normal were excluded. Fi-
nally we excluded patients on antidepressants, hypnotics,
opioids, NSAIDs, antihistamines, anxiolytics, sedatives, sys-
temic corticosteroids if the drugs were given during the
24 hours prior to surgery, except for routine preoperative
anxiolytic medication. Long-acting NSAIDs (e.g., oxapro-
zin, piroxicam), acetylsalicylic acid, or other anti-platelet
drugs were stopped 7 days before the first dose of study
medication.
Prior and concomitant medications and procedures
On the evening before surgery all subjects received dika-
liumclorazepate (Tranxilium) 20 mg by mouth for sedation.
On the morning prior to surgery all subjects received mid-
azolam (Dormicum) 7.5 mg orally for anxiolysis.
All patients received general anesthesia using volatile
anesthetics (desflurane or isoflurane) and fentanyl. The
remaining management of general anesthesia was left to
the discretion of the individual anesthesiologist. None of
the patients received neuraxial analgesia. During open
prostatectomy, after removal of the prostate and place-
ment of the urinary catheter, at least one drain was
placed in the perivesical space. At the end of the oper-
ation patients were extubated and transferred to the
intensive or intermediate care unit for monitoring over-
night. Oral fluid intake was permitted on the day of
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venously to maintain hydration during this period (up to
3,000 mL). In the evening following surgery, all subjects
received enoxaparin 20 mg as thrombembolism prophy-
laxis. Patients also received up to 20 mg/d of dikalium-
clorazepate (Tranxilium) if requested.
Randomization and blinding
Subjects were randomized upon arrival to the post-
anesthesia care unit (PACU), according to a specific
identification that had been assigned at the preoperative
visit. The clinical site’s pharmacist or authorized site
personnel allocated the subject into either the parecoxib
or the placebo arm using a computer generated random
list. In order to preserve the double-blind assignment,
treatments were prepared by a third person not being in-
volved in the evaluation of subjects. All study medica-
tions were administered as a clear solution using 2 ml
syringes.
Study medication and rescue analgesia
The first dose of the study medication (parecoxib 40 mg
or placebo intravenously) was administered upon patients’
arrival in the PACU by the anesthesiologist. Subsequent
doses of the study medication (parecoxib 20 mg or pla-
cebo) were administered by a study staff nurse every
12 hours (±1 h) until postoperative day 2 (48 ± 1 h) after
skin closure. Patients received patient controlled analgesia
using morphine (1 mg/ml) for postoperative analgesia
with the following setting: no continuous infusion, bolus-
dose 1 mg, lock-out time 10 min, 4-h dose limit 40 mg).
Measurements
All subjects underwent scheduled visits 24 (±1 h) and 48
(±1 h) hours, after receiving the first dose of the study
medication. Opioid consumption and all items needed
to calculate the modified-brief pain inventory-short form
(m-BPI-sf ) (pain perception (pp) score and pain interfer-
ence (pi) score), the opioid-related symptom distress
scale (OR-SDS), and the Overall Benefit of Analgesic
Score (OBAS), were assessed.
The m-BPI-sf consists of a four-item pain severity do-
main (worst pain, least pain, average pain, and current
pain) and a seven-item pain interference domain (gen-
eral activity, mood, walking ability, relations with others,
sleeping, coughing, deep breathing, and concentration).
Both domains are rated on a 10 point scale, and the two
domains are reported as composite scores calculated as
the average of the respective items [21]. The OR-SDS as-
sesses 3 symptom distress dimensions (frequency, sever-
ity, bothersomeness) for 12 opioid related symptoms on
a 4 point scale. The average of these latter dimensions
reflects the respective symptom specific score. The com-
posite OR-SDS is calculated as the average of the 12symptom specific scores. The OR-SDS is a validated tool
for assessing if reduction in opioid use translates into a
reduction of the incidence and severity of opioid related
side effects [22]. In order to overcome the limitations of
every single score, we developed and validated the OBAS
by using pain scores, opioid consumption, as well as the
m-BPI-sf, and OR-SDS, previously [23]. The OBAS com-
bines measurements of pain intensity, opioid related
adverse events, and also patients’ satisfaction (global
evaluation). Accordingly, we believe it is an important
outcome variable that reflects a patient’s subjective bene-
fit from postoperative multimodal pain therapy.
Furthermore, we measured the intra-and postoperative
decrease in serum hemoglobin concentration (Hb), and
transfusion requirements intraoperatively and during
48 hours following skin closure [24]. More specifically,
intra operative blood loss was defined as: [Hb g⋅dL−1]
pre–[Hb g⋅dL−1]post + intraOP RBCU; where ([Hb g⋅dL
−1]pre is the blood hemoglobin concentration preopera-
tively, [Hb g/dL]post is the blood hemoglobin concentra-
tion assessed postoperatively, and intraOP RBCU is the
number of red blood cell units (RBCU) transfused dur-
ing prostatectomy. Furthermore, we calculated the total
blood loss as: [Hb g/dL]pre–[Hb g/dL]@48 + RBCU
during 48 hours; where ([Hb g/dL]pre is the blood
hemoglobin concentration preoperatively, [Hb g⋅dL−1]
@48 is the blood hemoglobin concentration 48 h after
skin closure, and RBCU during 48 hours is the number
of red blood cell units (RBCU) transfused after prosta-
tectomy during the 48 hours after skin closure. Total
blood loss at 24 postoperative hours was calculated simi-
larly. However, as there were no data available for RBCU
transfused during the first 24 hours, calculations did not
account for transfusions.
Serious adverse events were monitored by daily chart
review, and by interviewing the Urologist in charge of
this study, in order to monitor for perioperative myocar-
dial infarction, stroke, pulmonary embolism, deep vein
thrombosis, and gastrointestinal or surgical bleeding.Statistical analysis
A prioiri sample size calculation was performed using a
two sided t-test with a type I error of 5%. Considering
an estimated drop-out rate of 15% and an expected re-
duction in morphine consumption by 25%, a total of 76
individuals per group was calculated to achieve a power
of 80%.
All data were analyzed using Prism 5 for Mac OS X, Ver-
sion 5.0d (Graph Pad Inc., La Jolla, California). Data were
tested for normality using the Kolmogorov-Smirnov test
with Dallal and Wilkonson approximation of the Lillifores
method, where appropriate. Data were analyzed using
t-test, Mann–Whitney-U test, or chi-squared test as noted
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(25th/75th percentile).
Morphine consumption (primary), and blood-loss (sec-
ondary) during the first 48 h, and variables on OBAS,
m-BPI-sf score, and OR-SDS taken at 48 h after skin
closure were compared between groups using Mann–
Whitney-U-test.
We applied a multiple regression analysis model using
postoperative decrease in hemoglobin concentration as
the dependent variable and included independent va-
riables that we considered might affect postoperative
blood loss during parecoxib therapy: age, activated par-
tial thromboplastin time (aPTT), Quick, platelet count,
test drug.
The incidence of adverse events was compared be-
tween groups using chi-squared tests.
Results
Patients
A total of 105 patients (52 parecoxib, 53 placebo) were
enrolled in this trial and received treatment. Of these
subjects, 96 patients (48 parecoxib, 48 placebo) received
the study medication for 48 hours postoperatively and
had complete data sets available. One patient had to be
excluded for protocol violation, another due to an ad-
verse event (hyperhydrosis, parecoxib group), and three
patients had to be excluded because of withdrawal of con-
sent (placebo group). Two patients from each group had
to be excluded since relevant data were missing (Figure 1).
Of the patients included in the final analyses, 34 (17 re-
ceiving parecoxib) were recruited at investigational centerFigure 1 Patient flow chart.one, 60 patients (31 receiving parecoxib) at investigational
center two, and two patients (both receiving placebo) were
recruited at investigational center three. The physical
characteristics and laboratory variables were comparable
in both groups (Table 1).
Efficacy
Mean morphine consumption was lower (24.4%) during
the first 48 hours following surgery in subjects receiving
parecoxib (43.1 ± 24.1 mg) (mean ± SD) as compared to
those receiving placebo (57.1 ± 28 mg, p=0.02) (Figure 2).
Parecoxib administration resulted in a significantly de-
creased OBAS at 48 hours after the first administration
(2 (0/4)) as compared to the placebo group (3 (1/5.25))
(p=0.01) (Figure 3A). Values of Opioid Related-Symptom
Distress Scale (OR-SDS) were lower in patients receiving
parecoxib (0.3 (0.08/0.51)) compared to the placebo
group (0.4 (0.2/0.83)) (p=0.03, Figure 3B).
Calculation of the pain severity (ps) and the pain inter-
ference (pi) scores of the Modified-Brief Pain Inventory-
Short Form (m-BPI-sf ) revealed that parecoxib was
effective in reducing patients’ pain severity (1(1/2) versus
2(2/3), p < 0.01, Figure 3C) as well as pain interference
with patients’ life (1(0/1) versus 1(1/3), p < 0.01,
Figure 3D).
Blood loss and transfusion requirements
Intraoperative decrease in Hb was not significantly dif-
ferent between both groups (p=0.26). Median decrease
in Hb was 3.2 g⋅dL−1(2.1/3.7) in the parecoxib group
and 2.3 g⋅dL−1(1.7/3.8) in the placebo group.
Table 1 Descriptive data
Parecoxib Placebo
Number of subjects 52 53
Subjects excluded 4 5
Age (years) 64.4 (±7.5) 65.0 (±7.2)
Age (years) range 47-83 46-75
Haemoglobin (g⋅dL−1) 14.5 (±1.2) 14.5 (±1.5)
aPTT (s.) 30 (±3.3) 30.1 (±3.6)
Quick (%) 100 (88 / 100) 97.5 (94 / 100)
Platelet count (x109/L) 244 (±62) 224 (±56)
Data are given as numbers, mean (± standard deviation), or median (25th/75th
percentile), as appropriate. There were no significant differences between groups.
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skin closure was however significantly greater in the par-
ecoxib group (4.3 g⋅dL−1(3.6/4.9)) as compared to the
placebo group (3.2 g⋅dL−1(2.4/5.0) (p=0.02) (Figure 4).
Multiple regression analysis using decrease in Hb
assessed at 24 hours postoperatively as the dependent
variable and age, activated partial thromboplastin time
(aPTT), Quick, platelet count, and test drug as inde-
pendent variables confirmed that the test drug (i.e. pare-
coxib or placebo) was the only independent factor
associated with higher decrease in Hb during 24 hours,
postoperatively (p=0.026). Data on the variables included
are listed in Table 1. However, the effect was no longer
statistically significant when analyzing the decrease in
Hb at 48 hours. The median decrease in Hb at 48 hours
was 4.4 g⋅dL−1(3.8/5.4) in the parecoxib group and
3.85 g⋅dL−1(2.8/5.4) in subjects receiving placebo
(p=0.12, Figure 4).Figure 2 Cumulative amount of morphine used at 48 hours
following skin closure. Mean (symbols) and standard deviation
(error bars). Morphine consumption was significantly (24%) less in
the parecoxib group vs. placebo.Transfusion requirements were similar between groups.
One patient from each group had 1 RBCU transfused
within the first 48 hours following skin closure. Four sub-
jects from the parecoxib group and 1 subject from the pla-
cebo group had 2 RBCU transfused within the first
48 hours after surgery.
Adverse events
All patients were included in the analyses of safety.
Throughout the study period, a total of 116 adverse
events (AEs) were observed in 43 subjects (83%) in the
parecoxib group and 109 AEs in 42 subjects (79%) in the
placebo group, respectively. The most common adverse
events, occurring in 2 or more subjects are listed in
Table 2. There were no statistical differences in the fre-
quencies of the listed adverse events between the treat-
ment and the placebo group, respectively, as determined
using a Fishers exact test. Most adverse events were
classified mild (n=156) to moderate (n=62) in both
groups. However, serious or severe adverse events (n=7)
were reported in two subjects in the parecoxib group
(thrombocytosis and hyperhidrosis), and 5 subjects in
the placebo group (diarrhea, pyrexia, confusional state,
and hemorrhage). Only one patient in the parecoxib
group discontinued treatment, secondary to severe hy-
perhidrosis, which started 20 minutes after receiving the
study drug. Of the adverse events in the parecoxib arm,
a total of three (hypokalemia, acute renal failure, and hy-
perhidrosis) were classified as being treatment related.
Discussion
This study demonstrates that postoperative parecoxib
co-administration with morphine in patients undergoing
radical open prostatectomy significantly decreases mor-
phine consumption by an average of 24%. The finding
that parecoxib reduces opioid consumption as part of a
multimodal postoperative analgesic strategy is not un-
anticipated, as this effect has been previously demon-
strated. However, this study improves upon previous
studies by assessing more than just opioid consumption.
We assessed the effect of multimodal analgesia with par-
ecoxib on patient satisfaction and side effects using pre-
viously validated clinically relevant scoring systems,
finding that multimodal analgesia improves the quality
of pain relief whilst also reducing unpleasant side effects.
However, our study also suggests that parecoxib use in
patients undergoing radical open prostatectomy may be
associated with increased perioperative blood loss in the
first 24 hours after surgery.
Postoperative analgesia
In 2001, the Joint Commission on Accreditation of Hos-
pital Organizations advocated pain management a prior-
ity in delivering good care [25]. This led to an increase
Figure 3 Scoring system variables of analgesic efficacy at 48 hours following skin closure. OBAS (A), OR-SDS score (B), m-BPI-sf pain
perception score (C), and m-BPI-sf pain interference score (D). Box-plots of quartiles (boxes), median (line within box), minimum, and maximum
(error bars). All measurements of analgesic efficacy were significantly less in the parecoxib group vs. placebo.
Figure 4 Decrease in hemoglobin concentration (Hb) measured
as: Hb [g⋅dL−1] preoperatively–Hb [g⋅dL−1] at 48 hours following
skin closure + RBCU during 48 hours; where RBCU during 48 hours
is the number of red blood cell units (RBCU) transfused after open
prostatectomy until 48 h after skin closure. Box-plots of quartiles
(boxes), median (line within box), minimum, and maximum (error bars).
Decrease in Hb was significantly higher in the parecoxib group vs.
placebo at 24 hours.
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tients, in a bid to minimize patient pain levels. Opioids
are highly effective analgesics in the treatment of post-
operative pain, however their use is associated with po-
tentially serious and often distressing side effects for
patients. Respiratory depression, alterations in mental sta-
tus, nausea, vomiting and constipation/ileus are all known
side effects of opioid medication [26]. Multimodal anal-
gesia strategies aim to reduce opioid consumption and
thus opioid side effects whilst also improving overall anal-
gesic management and patient satisfaction by combining
opioid and non-opioid medications in the treatment of
postoperative pain [6]. NSAIDs are commonly used in
these multimodal strategies and have been proven to re-
duce postoperative opioid consumption [7].
Non-selective NSAIDs are not suitable for the man-
agement of pain in the immediate postoperative period
as they inhibit COX-1 expressed in platelets, leading to
reduced platelet aggregation and an increased risk of
bleeding. Selective COX-2 inhibitors avoid this un-
wanted side effect. The advent of Parecoxib, a selective
COX-2 inhibitor that can be administered parenterally,
made the use of NSAIDs as part of a multimodal pain
therapy regime in surgical patients more feasible. Pare-
coxib has been licensed for use in Europe for the short-
term treatment of postoperative pain. The efficacy of this







Anemia 6 (12) 4 (8) 0.53
Vertigo 0 (0) 3 (6) 0.24
Abdominal pain 3 (6) 1 (2) 0.36
Constipation 2 (4) 7 (13) 0.16
Diarrhea 4 (8) 8 (15) 0.36
Flatulence 6 (12) 10 (19) 0.42
Nausea 12 (23) 16 (30) 0.51
Vomiting 9 (17) 4 (8) 0.15
Pyrexia 1 (2) 4 (8) 0.36
Urinary tract
infection
8 (15) 7 (13) 0.79
Wound infection 2 (4) 3 (6) 1.0
Back pain 2 (4) 0 (0) 0.24
Hypokaliemia 2 (4) 2 (4) 1.0
Dizziness 2 (4) 2 (4) 1.0
Paresthesia 2 (4) 2 (4) 0.24
Confusion 0 (0) 2 (4) 0.5
Insomnia 3 (6) 1 (2) 0.36
Bladder pain 0 (0) 2 (4) 0.5
Urinary retention 2 (4) 1 (2) 0.62
Cough 1 (2) 2 (4) 1.0
Oropharyngeal pain 3 (6) 2 (4) 0.68
Deep vein
thrombosis
2 (4) 0 (0) 0.24
Hypertension 6 (12) 4 (8) 0.53
Hypotension 2 (4) 0 (0) 0.24
Lymphocele 6 (12) 2 (4) 0.16
There were no differences in the incidence of adverse events between parecoxib
and placebo. Results are given as numbers (%) of patients reporting an adverse
event.
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following major abdominal surgery has not been exten-
sively investigated.
Efficacy in reducing opioid consumption
The efficacy of analgesic drugs for postoperative anal-
gesia is considered to be procedure specific [27], and
most studies focus on the reduction of opioid require-
ments as their primary outcome measure [7]. In our
present study, parecoxib analgesia resulted in an average
reduction of cumulative morphine requirements by 24%
compared to placebo in patients undergoing open pros-
tatectomy. This finding is in accordance with previous
studies describing an opioid sparing effect of COX-2 in-
hibitors in the postoperative period [8-13]. However,
opioid sparing is not by itself considered a clinically
meaningful endpoint [7,28]. Thus, we examined othermeasurements assessing patients’ benefits from multi-
modal analgesia.
Parecoxib and patient satisfaction
Most studies assess the incidence of adverse events but
seldom use well established validated scores, like the
OR-SDS or the pain interference score derived from the
m-BPI-sf [29]. Since both pain related symptoms and
opioid related side effects are associated with patient sat-
isfaction [30], we performed additional assessment of the
OBAS which we have recently developed and validated.
As demonstrated, the OBAS correlated much better with
patient satisfaction than analyzing pain scores alone.
Furthermore, the OBAS yields higher resolution of anal-
gesic treatment effects of COX-2 inhibitors than pain
scores, OR-SDS and m-BPI-sf [23]. In the present study,
the opioid sparing effect of postoperative parecoxib trans-
lated into a significant reduction of OBAS, OR-SDS, and
m-BPI-sf scores, indicating that patients perceived signi-
ficant benefit from parecoxib, namely reduced pain in-
tensity, reduced opioid associated side effects, and less
interference with their lives (general activity, mood, walk-
ing ability, relations with others, sleeping, coughing, deep
breathing, and concentration) [21]. These findings are in
accordance with other studies assessing OR-SDS and/or
m-BPI scores [13,31,32] and indicate that opioid sparing
effects of non-opioid analgesics may translate into clinical
benefit in patients analgesia.
Parecoxib and postoperative bleeding
In our study, the postoperative use of parecoxib was not
associated with increased bleeding, as measured by the
total blood loss at 48 hours postoperatively, a priori de-
fined secondary outcome. However, there was a trend
towards higher blood loss at this predefined time inter-
val and a trend towards higher transfusion requirements
(5 patients in the parecoxib group vs. 2 patients in the
placebo group receiving any RBCU transfusion). Fur-
thermore, the incidence of postoperative anaemia was
1.5 times higher in patients receiving parecoxib. How-
ever, this difference was not found to be statistically signifi-
cant. In addition, analyses of the postoperative decrease in
Hb revealed a higher decrease in Hb in patients receiving
parecoxib during the first 24 h following surgery compared
to placebo. The lack of statistical significance in the total
blood loss at 48 hours postoperatively might be due to the
relatively small size of the study population. While use of
classical NSAIDs is associated with approximately a six
fold increase in surgical bleeding complications (2.4%)
compared to placebo (0.4%) [33], COX-2 inhibitors are
generally considered to not increase bleeding risk. How-
ever, a trend towards an increased incidence of postopera-
tive anemia associated with parecoxib (14.1% vs. 10%) has
been previously reported [11]. However, given the data by
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cance in our data, the effect of parecoxib on postoperative
bleeding is still not clearly defined, thus warranting further
research in order to ensure patient safety in the postopera-
tive period.
As stated earlier, COX-2-inhibitors do not affect platelet
aggregation, as shown by impedance aggregometry, throm-
boelastometry, and platelet function analyzer (PFA-100)
assays [34,35]. Nevertheless, COX-2 inhibitors may in-
crease blood loss via drug interactions [36,37]. Parecoxib
and its metabolite valdecoxib are suspected to potentiate
warfarin’s effects since both COX-2 inhibitors exert inhibi-
tory effects on CYP2C9 [38], an enzyme that also metabo-
lizes warfarin. Co-medication with warfarin and parecoxib
has been shown to increase the propensity to bleeding
[38]. In addition, we speculate that it might be possible
that COX-2 inhibitors, similar to aspirin [39] may affect
fibrinolysis and that increased blood loss might be
procedure-specific [40].
Limitations
Our study has certain limitations. Most centers now pre-
fer laporascopic or robot-assisted-laporascopic versus
open prostatectomy and open radical postatectomy is
only performed in about 25% of cases [41]. Accordingly,
one could argue that our study population does not repre-
sent a typical cohort of patients undergoing prostatectomy.
However, pain and morphine consumption following open
radical or robot-assisted laparoscopic prostatectomy are
similar [42]. Another limitation of our study relates to un-
balanced patient enrollment in the three centers. While in-
vestigational centers one and two enrolled 34 and 60
patients, respectively, center three enrolled only 2 patients.
Removing these two patients from our analyses did not
change our results.
Finally, our data regarding blood loss have to be inter-
preted cautiously. First of all our study was designed to
assess blood loss at 48 hours not as a primary, but as a
secondary outcome measure and the study was originally
powered based on the expected opioid sparing effect.
Perioperative blood loss is affected by several confound-
ing factors such as surgical technique. Our finding of in-
creased blood-loss in the parecoxib group is hypothesis
generating. Since our findings are in line with the obser-
vation of others [11] we feel that the effects of COX-2
inhibitors on blood loss should be further evaluated in
future trials.
Conclusions
In summary, our data show that the perioperative use of
parecoxib for adjunctive analgesia following open prosta-
tectomy is associated with significant opioid sparing that
translates into clinical analgesic benefit to patients. Pare-
coxib may however increase perioperative blood loss.Competing interests
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